Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

This study is to preform a comparative pharmacokinetic study of Dronabinol XL AdVersa® versus the listed drug.

X
Trial Profile

This study is to preform a comparative pharmacokinetic study of Dronabinol XL AdVersa® versus the listed drug.

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dronabinol (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Pharmacokinetics; Registrational
  • Sponsors Tetra Bio Pharma
  • Most Recent Events

    • 27 Sep 2018 According to a Tetra Bio Pharma media release, the company anticipates submitting a New Drug Application to commercialize PPP002 in Q1 2019.
    • 13 Jun 2018 According to a Tetra Bio Pharma media release, if this trial proves the equivalence of test product to the reference product, the company anticipates filing for approval under 505(B)2 route in the USA in Q4 of 2018.
    • 13 Jun 2018 According to a Tetra Bio Pharma media release, the company expects to launch this study in the third quarter of 2018.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top